The Oral cGVHD as a Predictive Factor of Graft Versus Leukaemia Effect in Patients Who Received an Allograft

Centre Hospitalier Universitaire de Nice

Status: Completed

Conditions: Allografts; Oral cGVHD

Treatments: Other: Evaluation of oral cGVHD

Study type: Observational

Funder types: Other

Identifiers

NCT07271498

25Hemato01

Details and patient eligibility

About

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the standard treatment for many malignant blood disorders. Its effectiveness is based on the graft-versus-leukemia (GVL) effect, which is intrinsically linked to the occurrence of graft-versus-host disease (GVHD). While GVHD reflects favorable alloreactivity, its severe forms increase While GVHD reflects favorable allograft reactivity, its severe forms increase non-relapse mortality (NRM) and impair quality of life. Currently, there is no simple clinical marker that can predict or monitor the efficacy of the GVL effect. The investigators therefore hypothesized that chronic oral GVHD, a common and easily identifiable manifestation, could reflect beneficial alloreactivity, reflecting a balance between GVL effect and toxicity. The investigators conducted a prospective, observational, single-center study including patients transplanted at the Nice University Hospital between October 2023 and May 2025, followed by a standardized stomatological protocol before and after transplantation.

Enrollment: 93 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who received an allograft between octobre 2023 and May 2025 at CHU de Nice.

Exclusion criteria

• Patients who did not received an allograft

Trial design

93 participants in 1 patient group

Patient with oral cGVHD

Treatment:

Other: Evaluation of oral cGVHD